IBC Research Fdn

Super timely as FDA approved Dato in 1L metastatic TNBC for those who are not PD-1/PDL-1 I candidates based on the phase 3 TB-02 trial today!

Most ppl don't have a clue about life with stage 4 (metastatic) breast cancer. Abigail's lived experience speaks volumes...#timetoxicity

📣 Four new #breastcancer #FDA approvals in the first 3 wks of May! #OncTwitter #MedTwitter, if you need ONE central place with concise info on cancer drug approvals, share & bookmark this site: fda.gov/drugs/resource…. #Regulatory #MedEd

@stage4kelly Maybe I can finally get there in 2027!

Added to calendar! Open for speaking opportunities (as a full time, unpaid MBC advocate and patient I need someone to cover my ✈️ & 🏨!)#bcsm

@LauraEsfeller @flyPSP @SWOG Have a good meeting & tell everyone I said hello!

Departing from my favorite airport @flyPSP to San Francisco for @SWOG #SWOGSpring26! Excited to see some of my favorite folks & talk all things #oncology & #clinicaltrials! #patientadvocate

We, in the #advocate community especially appreciate these #topabstracts in breast cancer lists. They are a point of reference to help identify what the research community finds important/of interest. Keep sharing!!#ASCO26

How menopause alters cancer susceptibility: Insights from the most detailed breast tissue map yet oncology-central.com/how-menopause-…

The #OncoAlertColloquium 2026 Breast Malignancies🚨 #EBCC15 Presentation by Dr. Erika Hamilton🇺🇸 of Sarah Cannon: ER+ Metastatic #BreastCancer WATCH HERE👉 buff.ly/Saqoh4O Exciting data over the past year from trials of novel endocrine agents 📊 Oral SERDs continue to show efficacy in ESR1-mutant HR+/HER2- MBC, and we now have two FDA-approved oral SERDs: elacestrant and imlunestrant ✅ Vepdegestrant, a novel PROTAC inhibitor, has also outperformed fulvestrant as 2L therapy in ESR1-mutant HR+/HER2- MBC and is very well tolerated. If FDA approved, this would offer a monotherapy option after progression on 1L CDK4/6i + ET. Combination strategies have shown boosted efficacy (EMBER-3, evERA), though with increased toxicity ⚖️ The phase 3 SERENA-6 trial evaluated an early-switch strategy, substituting camizestrant for AI in 1L CDK4/6i-based therapy for patients with ESR1m detected in ctDNA without radiographic progression. Camizestrant + CDK4/6i prolonged PFS by ~7 months vs AI + CDK4/6i. While universal adoption remains debated, these data add to growing evidence that ctDNA testing may enable early-switch strategies before progression 🧬 Eagerly awaiting results from 1L oral SERD + CDK4/6i trials 👀 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @Icro_Meattini 🇮🇹 Dr. Roberto Salgado 🇧🇪 @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @itrisabel 🇪🇸 @ESSOnews @ElisaAgostinett 🇧🇪 @RebeccaDSing 🇸🇬 @LazarPo31787807 🇷🇸 @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JaniceTNBCmets @Prof_Nadia_H @MammaMiaMagazin @itrisabel #OncoAlertAF @nataliagandur @acampsmalea @FernandoOnco @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @DrRishabhOnco @Onco_Cifu88 Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

Less than 1% of the administered ADC dose reaches the tumor after each infusion

Thanks for all you do!! #HappyDoctorsDay....we appreciate the good care & research work!

If you make under $184k, you pay a 12.4% Social Security tax rate. Everything after that cap is exempt from the tax. So if you make $1 million per year, you pay about 2.2%. And it's 0.002% for billionaires. If we lifted the cap, Social Security could be funded for decades.

PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer cancertherapyadvisor.com/news/phila-pyr…

Want to make a donation to support @IBCResearch? We're now registered with Pledge, easy one stop for donating $$, Stock, etc. pledge.to and search for IBC Research Foundation!! Thanks!

Results from @TheTBCRC 049 trial of tucatinib/cape/trastuzumab for HER2+ LMD now published in @NatureCancer. Most patients had improved neurological deficits, PFS was 4.4 months and OS 10 months, with 41% of patients alive at 18 months. nature.com/articles/s4301…

Front Line post by @SWOG chairs @DrDawnHershman & @PrimoLaraMD: The Next Era of SWOG Success We see trials that are more streamlined & decentralized, that integrate community & advocate voices, that ask questions only public-powered research will answer. swog.org/news-events/ne…

What Are PBMs, and How Do They Impact Drug Costs and Cancer Care? cancertherapyadvisor.com/features/what-…

Happy St Patrick’s Day from Shaun and the flock! ☘️ #HappyStPatricksDay #LuckOfTheIrish #StPatricksDay

Singer and salon owner Shirley Joseph (@ShellzWithAZ) was only 33 when she was diagnosed with #InflammatoryBreastCancer. The news put much of her career on hold, but fortunately she was able to lean on her husband Mike Joseph for support. Learn more about their journey and how @DanaFarber's Leticia Varella, MD, (@VarellaLeticia1) and the #IBC Program, supported this young couple. #BreastCancer youtube.com/watch?v=6Oui4n…

Older Breast Cancer Survivors Who Received Taxane-Based Chemo Report Late-Effect Neuropathy, Balance Problems cancertherapyadvisor.com/news/older-bre…